JPRN-UMIN000037514招募中未知
Baricinitib reduction after achieving remission may keep remission in RA patients - BREAK study
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 90years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Those who were considered not suitable for the study by researchers
研究者
相似试验
招募中
3 期
Baricitinib in patients with relapsing or naïve dermatomyositis (BIRD)2024-511899-32-00Assistance Publique Hopitaux De Paris62
已完成
不适用
Reinduction with lapatinib followed by retreatment with trastuzumab-based therapy after disease progression multi-HER2 targeted therapies in HER2-positive metastatic breast cancerHER2-positive metastatic breast cancerJPRN-UMIN000014189JFCR Breast Med Oncol
进行中（未招募）
不适用
Clinical trial on induction of remission with bortezomib (Vel), cyclophosphamide (C) and dexamethasone (D) in patients until the age of 60 with untreated multiple myeloma and planned high dosage chemotherapy: (VelCD), (DSMM XIa)ntreated patients with cytologically and/or histologically established multiple myeloma (Durie and Salmon stage II or III) requiring treatment with measurable myeloma protein in the blood or urine.MedDRA version: 8.1Level: LLTClassification code 10028228Term: Multiple myelomaEUCTR2005-003902-27-DEORTHO BIOTECH, Division of JANSSEN-CILAG GmbH400
招募中
3 期
Evaluation of therapeutic effect of baricitinib in patients with severe pneumonia requiring non-invasive ventilation induced to Covid 19Acute viral infection caused by the corona virus (COVID-19).COVID-19, virus identifiedU07.1IRCT20220508054780N1Mashhad University of Medical Sciences15
已完成
3 期
Influence of macrolide maintenance therapy and bacterial colonisation on exacerbation frequency and progression of COPD, a randomized double-blind placebo-controlled trialemphysemachronic bronchitisNL-OMON36440Amphia Ziekenhuis92